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The E3 ubiquitin ligase Pellino 1 (Peli1) is a microglia-specific mediator of autoimmune
encephalomyelitis. Its role in neurotropic flavivirus infection is largely unknown. Here, we
report that mice deficient in Peli1 (Peli1–/–) were more resistant to lethal West Nile virus
(WNV) infection and exhibited reduced viral loads in tissues and attenuated brain
inflammation. Peli1 mediates chemokine and proinflammatory cytokine production in
microglia and promotes T cell and macrophage infiltration into the CNS. Unexpectedly,
Peli1 was required for WNV entry and replication in mouse macrophages and mouse and
human neurons and microglia. It was also highly expressed on WNV-infected neurons and
adjacent inflammatory cells from postmortem patients who died of acute WNV encephalitis.
WNV passaged in Peli1–/– macrophages or neurons induced a lower viral load and
impaired activation in WT microglia and thereby reduced lethality in mice. Smaducin-6,
which blocks interactions between Peli1 and IRAK1, RIP1, and IKKe, did not inhibit WNV-
triggered microglia activation. Collectively, our findings suggest a nonimmune regulatory
role for Peli1 in promoting microglia activation during WNV infection and identify a
potentially novel host factor for flavivirus cell entry and replication.
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Introduction
Pellino 1 (Peli1), an E3 ubiquitin ligase, is an important regulator 
in innate and adaptive immunity. It is essential for NF-κB acti-
vation induced by TIR domain–containing, adapter- inducing 
IFN-β/TLR–mediated (TRIF/TLR) signaling in innate immune 
cells such as macrophages and DCs (1). In microglial cells, in 
which Peli1 is predominantly expressed in the brain, Peli1 reg-
ulates TLR/MyD88 signaling by promoting the degradation of 
TNF receptor-associated factor 3 (Traf3), a process which leads 
to microglia activation during the course of induction of exper-
imental autoimmune encephalomyelitis (EAE) (2). Peli1 is also 
implicated in the regulation of adaptive immune cell functions. 
For example, it is a critical factor in the maintenance of periph-
eral T cell tolerance by regulating c-Rel via its K48 ubiquitina-
tion (3). Peli1 upregulation also plays a role in B cell lymphoma 
tumorigenesis (4).
West Nile virus (WNV), a mosquito-borne, single-stranded 
flavivirus that caused outbreaks in Asia, Europe, and Australia, has 
been the leading cause of viral encephalitis in the United States 
for more than a decade (5, 6). The features of acute illness range 
from WN fever to neuroinvasive conditions, including meningitis, 
encephalitis, acute flaccid paralysis, and death (7). In addition, up 
to 50% of convalescent WNV patients have been reported to have 
long-term neurological sequelae or chronic kidney disease (8–16). 
Currently, there is no specific therapeutic agent for the treatment 
of WNV infection, and an approved vaccine is not available for 
humans. Studies in animal models suggest that WNV-induced 
CNS disease is caused by neuronal degeneration, a direct result 
of viral infection, and/or by bystander damage from the immune 
response to the pathogen in the CNS (17, 18) that is induced by 
infiltrating inflammatory cells and CNS-resident cells, including 
microglia/macrophages, neutrophils, and lymphocytes (19–23). 
Microglial cells, the resident macrophages of the CNS that express 
various pattern recognition receptors (PRRs), become activated 
and produce innate proinflammatory molecules upon encoun-
tering microbial infection. Microglia activation in the CNS is the 
hallmark of acute WNV infection (24, 25). It was also shown to 
drive neuronal and synaptic loss, which together contributes to 
memory impairment in WNV-induced chronic cognitive sequelae 
(26). The underlying immune mechanisms of microglia activation 
are not clearly understood. Here, we hypothesize that Peli1 medi-
ates the activation of microglia and promotes neuroinflammation 
during lethal WNV infection. Unexpectedly, we found that Peli1 is 
required for WNV entry and replication in both peripheral myeloid 
cells and CNS-resident cells. In particular, we found that defective 
WNV replication in Peli1-deficient microglia and neurons directly 
contributes to attenuated neuroinflammation in the CNS and ulti-
mately decreases host susceptibility to lethal encephalitis.
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Thus, CNS inflammation started earlier and was more severe in 
WNV-infected WT mice than in Peli1–/– mice. No histopathologi-
cal differences were noted in naive mouse brains between the WT 
and Peli1–/– groups (Supplemental Figure 1; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI99902DS1).
Peli1–/– mice exhibit impaired innate cytokine production, but 
modestly enhanced adaptive immune responses in the periphery. Peli1 
is known to facilitate TRIF-dependent TLR signaling and proin-
flammatory cytokine production (1). Following WNV infection, 
Peli1 expression was increased in the blood of WT mice (Sup-
plemental Figure 2A). The RNA levels of IFN-α  (Ifna) and IFN-β 
(Ifnb) on day 6, IL-6 (Il6) and TNF-α (Tnfa) on days 3 and 6, and 
Il12 on day 3 were all diminished in Peli1–/– mice (Supplemental 
Figure 2B). Blood plasma protein levels of IL-1β and IL-10 were 
also reduced in Peli1–/– mice (Supplemental Table 1), though no dif-
ferences were noted in plasma IFN-γ or IL-17 levels between the 
2 groups of mice. To study the adaptive immune responses in the 
periphery, we first measured antibody production in the blood. 
WNV-specific IgM responses were modestly enhanced in Peli1–/– 
mice on days 3 and 9 p.i. (Supplemental Figure 2C). WNV-specific 
IgG responses were similar between the 2 groups of mice (Sup-
plemental Figure 2D). Peli1 is also known to negatively regulate T 
cell signaling (3). We next collected splenic tissues from naive and 
Results
Peli1–/– mice are more resistant to systemic WNV infection. Peli1 pro-
motes microglia-mediated brain inflammation in the course of 
EAE induction (2). To investigate the role of Peli1 in WNV enceph-
alitis, we infected WT and Peli1–/– mice i.p. with 100 focus-forming 
units (FFU) of the WNV 385-99 strain and monitored them dai-
ly for survival (Figure 1A). Peli1–/– mice (39% survival) were more 
resistant to WNV infection than were WT controls (9.5% survival). 
To further understand the viral pathogenesis, we measured viral 
burden in the peripheral organs and brain. Peli1–/– mice had lower 
viremia on days 2 and 3 post infection (p.i.) and decreased splen-
ic viral loads on day 6 compared with WT mice (Figure 1, B and 
C). WNV crosses the blood-brain barrier (BBB) and infects the 
CNS around day 3 in mice (25). Viral RNA levels in Peli1–/– mouse 
brains were more than 15-fold lower than those of WT mice on 
day 6 p.i. (Figure 1D). This trend continued but became insignif-
icant by day 9, when both groups of mice started to succumb to 
lethal WNV infection. On day 6 p.i., we noted meningitis (inflam-
mation of the leptomeninge) in WT mice, but not in Peli1–/– mice 
(Figure 1E). Inflammation further spread to the brain parenchyma 
(encephalitis), as seen on day 9 in the striatum, hippocampus, and 
cerebellum in both groups of mice. We found that encephalitis, 
particularly perivascular cuffing and microglia activation (cells 
with elongated nuclei), was much more extensive in the WT mice. 
Figure 1. Peli1–/– mice are more resistant to lethal WNV infection. (A) Survival of WT and Peli1–/– mice after i.p. injection with WNV 385-99. n = 21 WT 
mice; n = 23 and Peli1–/– mice. **P < 0.01 compared with the WT group (log-rank test). (B) Viremia was determined by FFA on days 2 and 3 p.i. Data are 
presented as the mean ± SEM (n = 3–6) of samples collected from 1 representative experiment of 3 similar experiments. (C and D) Viral loads in the spleens 
and brains of infected and noninfected (NF) mice were determined by qPCR. Data are presented as the mean ± SEM (n = 7–12) and were collected from 3 
independent experiments. (B–D) *P < 0.05 and **P < 0.01 compared with the WT group (unpaired, 2-tailed Student’s t test). (E) Representative H&E-
stained images are of brains collected from 4 or 5 WNV-infected mice per group at the indicated time points. Scale bar: 25 μm. Original magnification, ×20. 
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PRRs, and both cell types are permissive to WNV infection in the 
peripheral organs (27). To study Peli1-mediated innate immune 
responses upon WNV infection, we first measured viral loads in 
these 2 cell types by quantitative PCR (qPCR) and focus-form-
ing assays (FFAs) and found that both viral RNA levels and viral 
titers were significantly diminished in primary myeloid Peli1–/– 
macrophages and DCs compared with WT controls (Figure 2, A 
and B, and Supplemental Figure 3, A and B). We next performed 
virus attachment and entry assays to determine Peli1 involve-
ment in the WNV replication cycle. Macrophages from mice of 
both groups were incubated with WNV (MOI = 3 or 10) at 4°C for 
1 hour, allowing the virus to attach to the cell surface. After 1 hour 
of incubation, the cells were washed to remove unattached virus, 
and the amounts of viruses that had attached to the cell surface 
WNV-infected WT and Peli1–/– mice. We found no necrosis in any 
of the splenic sections examined. We noted a trend toward white 
pulp expansion resulting from germinal center proliferation in WT 
mice on days 3 and 6 p.i., but this returned to levels similar to those 
in naive mice by day 9; in Peli1–/– mice, the expansion was continu-
ously enhanced (Supplemental Figure 2, E and F). On day 7, both 
CD4+ and CD8+ splenic T cells from Peli1–/– mice produced more 
IFN-γ than did those from WT mice upon ex vivo restimulation 
with WNV-specific peptides. CD4+ T cells from Peli1–/– mice also 
induced higher levels of IL-6 and IL-10 production (Supplemental 
Figure 2, G and H).
Peli1 is required for WNV entry and viral replication in macro-
phages and DCs, which further activates innate cytokine responses. 
Macrophages and DCs are innate immune cells expressing many 
Figure 2. Peli1 facilitates WNV replication in macrophages and promotes high mortality in vivo. (A and B) The viral load of WNV-infected macrophages 
was measured by qPCR (A) and FFA (B). Data are representative of 5 similar experiments and are presented as the mean ± SEM (n = 3–6). (C and D) Mac-
rophages were infected with WNV for 1 hour at 4°C, washed, and then collected to measure intracellular viral RNA by qPCR in the attachment assay (C). 
For virus entry (D), cells were subsequently resuspended in medium and incubated at 37°C. At the indicated time points, cells were washed to determine 
intracellular viral RNA levels (n = 6). (E and F) Thin-section transmission electron micrographs of WNV-infected macrophages. (E) Viral particles were 
observed at the plasma membrane at 0 minutes, in small, uncoated vesicles at 5 minutes, and in double-membrane vesicles at 10 hours. (F) Quantitation 
of 10 fields of view of ultrathin sections. (G) Negative staining micrographs of WNV. Virions ranged in size from 41 nm to 47 nm and 23.5 nm to 39.5 nm 
in supernatants of WT and Peli1–/– macrophages on day 4 p.i., respectively. (H) WT macrophages were infected at a MOI of 0.02 with viruses passaged in 
WT (WTP) and Peli1–/– (Peli1–/–P) macrophages. The viral load was measured by FFA on day 4 p.i. Data are representative of 2 similar experiments and are 
presented as the mean ± SEM (n = 4). Data in A–D and H were analyzed by unpaired, 2-tailed Student’s t test. *P < 0.05 and **P < 0.01 compared with the 
WT group. (I) Survival rates of mice injected i.p. with 100 FFU WNV passaged in WT macrophages and Peli1–/– macrophages (n = 7–9). *P < 0.05 compared 
with WT mice infected with WT macrophages (log-rank test).
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determined the infectivity of WNV that was passaged in WT or 
Peli1–/– macrophages. WNV passaged in Peli1–/– macrophages had 
a lower replication rate in WT macrophages compared with WNV 
passaged in WT macrophages (Figure 2H). Furthermore, we chal-
lenged WT and Peli1–/– mice with 100 FFU WNV passaged in WT 
or Peli1–/– macrophages. WT mice infected with WNV passaged in 
Peli1–/– macrophages showed an increased survival rate (28.5%, 
Figure 2I) compared with that of WT mice infected with WNV 
passaged in WT cells (0%). Peli1–/– mice infected with WNV pas-
saged either in WT macrophages (43%) or Peli1–/– cells (56%) also 
showed a similar resistance to lethal WNV infection.
We next determined whether Peli1 mediates immune respons-
es during WNV infection in macrophages and DCs. Following 
WNV infection, we found that Peli1 expression was upregulated 
in macrophages by day 4. In contrast, the other 2 Pellino family 
members, including Peli2 and Peli3, remained at low levels (Figure 
3A). Compared with WT cells, Peli1–/– macrophages had reduced 
Ifna and Ifnb RNA levels on days 1 and 4 after WNV infection (Fig-
ure 3, B and C). Production of inflammatory cytokines, includ-
ing IL-6 (Il6), TNF-α (Tnfa), and IL-12 (Il12), was also impaired 
in Peli1–/– macrophages by day 4 (Figure 3, D–F). WNV infection 
in Peli1–/– DCs also resulted in diminished levels of Ifnb, Il1b, and 
Il12 compared with WT DCs (Supplemental Figure 3C). PRRs, 
including TLR3 and TLR7, and retinoid acid–inducible gene I–like 
receptors (RLR)s, such as retinoid acid–inducible gene I (RIG-I) 
and melanoma differentiation antigen 5 (MDA-5), are involved 
in WNV recognition and trigger the signaling cascade leading to 
the production of type 1 IFNs and proinflammatory cytokines (25, 
29–31). To understand the role of Peli1 in PRR-mediated signal-
ing pathways, we treated WT and Peli1–/– macrophages with TLR 
agonists (Poly I:C for TLR3, CL097 for TLR7, and Poly I:C LyoVec 
were measured by qPCR. We noted that Peli1–/– macrophages had 
28% less virus attachment than did the WT cells (Figure 2C). Cells 
were further incubated at 37°C to initiate viral entry. At 1.5 and 5 
hours p.i., the infected cells were stringently washed to remove 
free virus as well as cell-surface–associated virus, and intra-
cellular viral RNA was quantified. As shown in Figure 2D, viral 
RNA levels in Peli1–/– macrophages were 27% to 54% lower than 
those in WT cells. These results indicated that Peli1 is involved 
in WNV attachment and entry. To confirm these results, we per-
formed ultrastructural analysis of macrophages from both groups 
of mice 0 minutes, 5 minutes, and 10 hours after exposure to 
WNV (Figure 2, E and F). At 0 hours, we detected 16 WNV par-
ticles, ranging from 41 to 46 nm in diameter, in association with 
the plasma membrane in WT macrophages, whereas a total of 7 
WNV particles were found in association with the plasma mem-
brane of Peli1–/– macrophages. At 5 minutes p.i., we detected 38 
viral particles with a diameter of approximately 42 nm in small, 
uncoated vesicles of the WT macrophages. However, only 11 WNV 
particles of the same size were identified in Peli1–/– macrophages. 
By 10 hours, there were 55 WNV viral particles with a diameter of 
42 nm inside the double-membrane vesicles of WT macrophages. 
Interestingly, we found 18 viral particles of much smaller size (~25 
nm) inside the double-membrane vesicles of Peli1–/– macrophages 
(Figure 2, E and F). On day 4 p.i., viral particles detected in the 
supernatants of WT macrophages ranged in diameter from 41 nm 
to 47 nm, which are dimensions similar to those previously report-
ed (28), whereas virions detected in the supernatant of Peli1–/– 
macrophages showed substantial variations in size, ranging from 
23.5 to 39.5 nm (Figure 2G). These observations suggest that Peli1 
not only plays a role in initial cell attachment and entry, but also in 
other aspects of the WNV life cycle within the host cells. We next 
Figure 3. WNV-induced antiviral immune responses in WT and Peli1–/– macrophages. (A–F) WT and Peli1–/– macrophages were infected with WNV and 
harvested at the indicated time points. (A) Peli1, Peli2, and Peli3 RNA levels in WT macrophages were measured on day 4 p.i. Data are representative of 3 
similar experiments and are presented as the mean ± SEM (n = 3). ##P < 0.01 compared with the noninfected group (unpaired, 2-tailed Student’s t test). 
(B–F) Cytokine RNA or protein levels were measured at the indicated time points by qPCR or Bio-Plex, respectively. Data represent the mean ± SEM of 5 
to 10 samples collected from 2 independent experiments. *P < 0.05 and **P < 0.01 compared with the WT group. (G) WT macrophages were infected at a 
MOI of 0.02 with WNV passaged in WT or Peli1–/– macrophages. On day 4 p.i., cytokine production was determined by qPCR. Data are presented as the fold 
increase compared with mock-infected cells (mean ± SEM) and are representative of 2 similar experiments (n = 4 per group). *P < 0.05 compared with the 
WTP group (unpaired, 2-tailed Student’s t test).
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The levels of reduction induced by WNV passaged in Peli1–/– cells 
were similar to cytokine levels in Peli1–/– cells induced by WT virus 
(Figure 3G and Supplemental Figure 3H). Collectively, these data 
show that Peli1 positively mediates antiviral cytokine responses 
mainly by a direct involvement in the WNV replication life cycle in 
macrophages and DCs.
Peli1 is predominantly involved in CNS inflammation during 
WNV infection. Peli1 was previously reported to be highly 
expressed by neural tissues (2). Here, we noted that Peli1 expres-
sion was induced in the brain on days 6 and 9 p.i. (Figure 4A). 
The mRNA levels of inflammatory cytokines including Il1b, Il6, 
and Tnfa and chemokines such as Ccl2, Ccl7, and Cxcl10 were 
decreased in Peli1–/– mice (Figure 4, B–G). Ifnb, but not Ifna, RNA 
levels were also reduced in Peli1–/– mouse brains (Supplemental 
Figure 4, A and B). To study the brain leukocyte phenotype, we 
for RLRs). We found that both Poly I:C and Poly I:C/LyoVec trig-
gered lower Ifna, Ifnb, Il6, and Il12 expression levels in Peli1–/– mac-
rophages. In contrast, stimulation with the TLR7 agonist induced 
similar antiviral cytokine responses in both groups of macrophages 
(Supplemental Figure 3, D–G). Peli1 is known to be dispensable 
for MyD88-dependent TLRs but is required for TRIF-dependent 
TLR signaling in macrophages and DCs (1). Consistent with the 
previous findings, we demonstrate that Peli1 positively regulates 
TLR3- and RLR-mediated, but not TLR7-mediated, innate cyto-
kine responses in macrophages. Finally, to understand the effects 
of defective viral replication on antiviral immunity, we infected 
WT macrophages with the same dose of WNV passaged once in 
WT or Peli1–/– macrophages. Interestingly, WNV passaged in Peli1–/– 
cells triggered diminished Ifnb RNA and IL-6 protein levels in WT 
macrophages compared with WNV passaged in WT macrophages. 
Figure 4. Peli1 mediates neuroinflammation in the CNS after WNV infection. (A) RNA levels of Peli1 in the brains of WT mice following WNV infection 
were determined by qPCR assay. Data are presented as the mean ± SEM of samples pooled from 2 to 3 independent experiments (n = 8). ##P < 0.01 com-
pared with the noninfected group (unpaired, 2-tailed Student’s t test). (B–G) RNA levels of cytokines and chemokines in the brain at the indicated time 
points were determined by qPCR assay. Data are presented as the mean ± SEM of 6 to 10 samples pooled from 2 independent experiments. (H–J) Brain 
leukocyte infiltration following WNV infection. (H) The number of brain leukocytes is presented as the mean ± SEM of 9 to 10 mice from 2 independent 
experiments, including naive microglial cells (NMGs), activated microglial cells (AMGs), macrophages (Mθs), and CD4+ and CD8+ T cells on day 9 p.i. (ana-
lyzed by flow cytometry). (I) Representative flow plot. (B–H) *P < 0.05 and **P < 0.01 compared with the WT group (unpaired, 2-tailed Student’s t test).  
(J) Survival of WT and Peli1–/– mice after i.c. injection with WNV 385-99 (n = 9 per group). *P < 0.05 compared with the WT group (log-rank test).
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performed flow cytometric analysis of these cells isolated on day 
9 and found that the number and percentage of infiltrating CD4+ 
T cells, activated microglial cells (CD11bhiCD45lo), and macro-
phages (CD11bhiCD45hi) were decreased by up to 60% in Peli1–/– 
mice (Figure 4, H and I, and Supplemental Figure 4C). To exclude 
the effects of Peli1 on WNV infection in peripheral tissues, we 
inoculated mice from both groups with WNV intracranially (i.c.) 
(Figure 4J). Peli1–/– mice showed resistance that was similar to that 
seen with systemic WNV infection (44% versus 11%, Peli1–/– ver-
sus WT). Collectively, these results indicate that Peli1 is involved 
in WNV encephalitis predominantly by mediating CNS infection 
and inducing neuroinflammation.
Peli1 promotes microglia activation via facilitation of WNV rep-
lication in neurons and microglia in mice and humans. Microgli-
al cells are involved in CNS neuroinflammation (24, 32) and are 
permissive to WNV infection (Supplemental Figure 5A). Peli1 is 
highly expressed on microglial cells (2) and was enhanced fol-
lowing WNV infection, however, Peli2 and Peli3 remained at low 
levels (Figure 5A and Supplemental Figure 5B). WNV triggered 
higher mRNA levels of inflammatory cytokines (Tnfa and Il12) and 
chemokines (Ccl2, Ccl4, and Cxcl10) in microglial cells (Supple-
mental Figure 5C). Interestingly, we observed that WNV infection 
was nearly abolished in both Peli1–/– primary microglial cells (Fig-
ure 5, B and C) and Peli1-depleted microglial cells (Supplemen-
tal Figure 5D), which was accompanied by diminished levels of 
inflammatory cytokines and chemokines (Figure 5D and Supple-
mental Figure 5E). Neurons are most permissive to WNV infection 
in the CNS (18, 33). WNV infection upregulated Peli1 expression 
on neurons by up to 200% (Figure 5E). WNV replication was also 
significantly reduced in Peli1–/– neurons compared with that seen 
in WT neurons (Figure 5, F and G). We found that mRNA levels of 
chemokines (Ccl2, Ccl7, and Cxcl10) and inflammatory cytokines 
(Il6 and Ifnb) were all diminished in WNV-infected Peli1–/– neu-
rons by day 4 (Figure 5H and Supplemental Figure 5F). Western 
blot analysis showed that phosphorylation levels of p38MAPK and 
p65 were both reduced in WNV-infected Peli1–/– neurons on day 3 
compared with levels in WT controls (Supplemental Figure 5, G 
and H), which suggests a role of Peli1 in the positive regulation of 
NF-κB and p38MAPK activation.
Immunostaining of postmortem hippocampal tissues from 
patients who died of acute WNV encephalitis showed membrane 
Peli1 on WNV-positive neurons and adjacent inflammatory cells, 
but not in the same region of age-matched control patients (Figure 
6A). Peli1 expression was also upregulated following in vitro WNV 
infection in SHSY-5Y–differentiated neurons and HMC3 cells (a 
human microglial cell line) (Figure 6, B and C) and WNV- infected 
PBMCs (Supplemental Figure 6A). Nevertheless, its expression 
was not changed in WNV-infected neural stem cell–derived neu-
rons or in THP1-derived macrophages (Supplemental Figure 6A). 
Knockdown (KD) of Peli1 expression in human microglial cells or 
SHSY-5Y–differentiated neurons decreased viral loads by 20% to 
35% by day 4 p.i. (Figure 6, D and E, and Supplemental Figure 6B). 
Peli1 deficiency also decreased IL-6, CCL2, and CCL5 production 
in human microglial cells (Figure 6, F–H). WNV infection did not 
Figure 5. WNV infection and induction of immune responses in microglia and neurons. (A) RNA levels of Peli1 in WT microglia on day 4 p.i. were 
determined by qPCR. Data are presented as the mean ± SEM and are representative of 2 independent experiments (n = 5). ##P < 0.01 compared with the 
noninfected group (unpaired, 2-tailed Student’s t test). (B–D) Primary microglia were infected with WNV 385-99 and harvested at the indicated time 
points. Data are presented as the mean ± SEM of 4 to 8 pooled samples from 2 independent experiments. (B and C) Viral load was measured on day 4. (D) 
Cytokine RNA levels were measured by qPCR at the indicated time points. (E–H) Primary mouse neurons were infected with WNV 385-99 and harvested at 
the indicated time points. Data are presented as the mean ± SEM (n = 6 per group). (E) RNA levels of Peli1 in WT neurons on day 4 p.i. ##P < 0.01 compared 
with the noninfected group (unpaired, 2-tailed Student’s t test). (F and G) Viral load was measured at the indicated time points by qPCR (F) and FFA (G. 
(H) Il6, Ccl2, Ccl7, and Cxcl10 RNA levels were measured by qPCR at the indicated time points. (B–D and F–H) *P < 0.05 and **P < 0.01 compared with the 
WT group (unpaired, 2-tailed Student’s t test).
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induce inflammatory cytokine or chemokine production in human 
neurons (data not shown). We noted that Peli1 KD (36% reduction, 
Supplemental Figure 6C) in human fetal cortical neural stem cell–
derived (hNSC-derived) neurons led to a 30% decrease on Ifnb 
levels on day 4 p.i. compared with levels in control siRNA–treated 
neurons (Supplemental Figure 6D). These data suggest that Peli1 
is involved in WNV replication in neural cells and induction of 
inflammatory cytokines and chemokines in human microglial cells.
To determine whether defective replication contributes to 
attenuated inflammatory responses in the CNS, we infected WT 
microglial cells with WNV passaged in WT or Peli1–/– neurons or 
macrophages. WT microglia infected with WNV grown in Peli1–/– 
cells had lower viral titers (Figure 7, A and B) and reduced mRNA 
levels of Il6, Ccl2, and Ccl7, but not of Tnfa or Cxcl10 (Figure 
7, C–E), compared with cells infected with WNV grown in WT 
cells. It is known that microglia respond to viral infection via 
activation of p38MAPK (24). Microglia infected with WNV pas-
saged in Peli1–/– cells also showed lower phosphorylation levels 
of p38MAPK than did cells infected with WNV passaged in WT 
neurons (Figure 7F). Smaducin-6, a membrane-tethered, palmit-
ic acid–conjugated peptide composed of amino acids 422–441 
of Smad6, was reported to interact with Peli1 and disrupt the 
formation of IRAK1, RIP-1, and IKK, but not MAPK-mediated 
signaling complexes (34). Smaducin-6 treatment did not block 
WNV infection or induction of inflammatory cytokine/chemo-
kine production in microglial cells or macrophages, though it 
decreased the levels of type 1 IFNs in macrophages (Figure 7, G 
and H, and Supplemental Figure 7). Overall, our results suggest 
that Peli1 is required for WNV replication in neural cells, which 
promotes p38MAPK activation in microglia and induction of 
inflammatory immune responses in the CNS.
Discussion
Peli1 has been reported to be an important mediator in the activa-
tion of NF-κB or p38MAPK in TLR-dependent signaling pathways 
(2). In this study, we have provided evidence that Peli1 facilitates 
WNV replication and mediates innate immunity in the periphery 
and CNS (Figure 8). In particular, on the basis of several facts, 
we conclude that Peli1 is predominantly involved in CNS neu-
roinflammation during WNV infection. First, although Peli1 pro-
motes WNV replication in myeloid cells (macrophages and DCs), 
it also positively regulates antiviral innate immune responses in 
these cells, which compromise its overall pathogenic effects in the 
periphery. Second, compared with myeloid cells, Peli1 expression 
is highly enriched in CNS-resident cells and is even upregulated 
following WNV infection. Third, Peli1 facilitates WNV replica-
Figure 6. Peli1 expression and its role in human cells during WNV infection. (A) Immunodetection of Peli1 (green), WNV antigen (WNV Ag) (red), and 
NeuN (purple), in postmortem hippocampal tissues from 1 control and 2 WNV-infected patients. Nuclei were counterstained with DAPI (blue). Scale bar: 8 
μm. Insets are images of sections stained with isotype control antibodies or serum (original magnification, ×63). (B and C) RNA levels of Peli1 in SH-SY5–
derived neurons and human microglia on days 1 and 4 p.i. were determined by qPCR. Data are presented as the mean ± SEM and are representative of 2 
similar experiments (n = 3–4). ##P < 0.01 compared with the noninfected group (unpaired, 2-tailed Student’s t test). (D–H) SHSY-5Y–derived neurons (D) 
and human microglial cells (E–H) were treated with control or Peli1 siRNA (Peli1 KD), infected with WNV 385-99 at 48 hours, and harvested at the indicated 
time points. (D and E) Viral load was measured on day 4 by qPCR. (F–H) IL-6, CCL-2, and CCL-5 production in microglial cells was measured on day 4 by Bio-
Plex assay. Data are presented as the mean ± SEM and are representative of 2 similar experiments (n = 4). (D–H) *P < 0.05  and **P < 0.01 compared with 
the control group (unpaired, 2-tailed Student’s t test).
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In line with findings of a previous report (37), we did not 
note a significant induction of inflammatory cytokine respons-
es in human neurons following WNV infection. Interestingly, 
WNV induced higher Peli1 expression on mouse neurons than on 
microglia. WNV-infected Peli1–/– mouse neurons had reduced lev-
els of NF-κB and p38MAPK activation, accompanied by impaired 
production of inflammatory cytokines and chemokines. We not-
ed that noninfected Peli1–/– mouse neurons also had lower levels 
p38MAPK activation, despite normal basal levels of cytokine pro-
duction compared with WT controls (data not shown). Thus, it is 
likely that Peli1 positively regulates inflammatory cytokine and 
chemokine responses in WNV-infected mouse neurons via NF-κB 
activation. Peli1 is known to activate NF-κB signaling via interac-
tion with RIPK1, another RIPK family member, which was recent-
ly shown to mediate neuronal chemokine induction and recruit T 
lymphocytes and inflammatory myeloid cells into the CNS (39). 
Whether Peli1 interacts with RIPK3 and regulates inflammatory 
responses remains to be investigated.
Smad6 and Smad7 are critical mediators for effective TGF-β1–
mediated suppression of IL-1R/TLR signaling via their simultaneous 
binding to discrete regions of Peli1 (40). Smaducin-6, which is com-
posed of amino acids 422–441 of Smad6, has been reported to disrupt 
the formation of IRAK1-, RIP1-, and IKKε-mediated TRIF signaling 
complexes, but not the phosphorylation of p38MAPK in macrophages 
(34). We found that Smaducin-6 did not inhibit WNV replication 
in microglia or macrophages. Further, Smaducin-6 did not block 
the production of inflammatory cytokines or chemokines in WNV- 
infected microglia or macrophages. These results support a role of 
Peli1 in the induction of inflammatory responses in both cell types 
during WNV infection via the promotion of p38MAPK activation.
Consistent with the findings in myeloid and CNS-resident 
cells, the production of type I IFNs, inflammatory cytokines, 
and chemokines in the blood and CNS tissues were all impaired 
tion in microglia and neurons, especially in the latter, which are 
the major cells infected during in vivo challenge. It also positive-
ly mediates NF-κB and/or p38MAPK activation in these cells and 
boosts a robust production of inflammatory cytokines and chemo-
kines, which attracts more inflammatory cells infiltrated from the 
periphery and ultimately contributes to lethal WNV encephali-
tis. Thus, Peli1 synergistically promotes virus dissemination and 
inflammation in the CNS. Last, Peli1–/– mice had similar levels of 
resistance compared with WT mice following systemic and direct 
intracranial WNV infection. This further indicates that Peli1 pro-
motes WNV-induced pathology primarily in the CNS.
WNV-induced CNS disease is partially caused by bystander 
damage from both the immune response induced in the CNS-resi-
dential cells (17, 18) and by infiltrating inflammatory cells (19–23). 
As shown in Figure 4H, Peli1–/– mouse brains had a significantly 
decreased number of infiltrating CD4+ T cells (P < 0.05), activated 
microglia (P < 0.01), and macrophages (P < 0.01). Both CCL2 and 
CCL7 are involved in monocytosis and monocyte accumulation in 
the brain (35), whereas CXCL10 helps recruit antigen-specific T 
cells (36). Microglial cells are the major producers of inflammato-
ry cytokines and chemokines in the CNS following WNV infection 
(25, 37). In vitro WNV infection in Peli1–/– or Peli1-depleted mouse 
and human microglia resulted in a lower viral load and induced 
impaired production of IL-6, CCL2, CCL7, and CXCL10. Neurons 
are the primary targets during in vivo WNV replication in the CNS 
(18, 38). WNV passaged in Peli1–/– neurons induced similarly lower 
levels of p38MAPK phosphorylation in WT microglia, and this was 
accompanied by impaired production of the chemokines CCL2 
and CCL7, but not CXCL10, in these cells. Collectively, our results 
suggest that Peli1 mediates proinflammatory cytokine and chemo-
kine production predominantly via facilitation of WNV replication 
in neural cells (microglia and neurons), which ultimately leads to 
macrophage/monocyte and T cell infiltration into the CNS.
Figure 7. Peli1 promotes p38MAPK activation in microglia via facilitation of WNV replication. (A–F) BV2 cells were infected at a MOI of 0.02 with viruses 
passaged in WT (WTP) and Peli1–/– (Peli1–/–P) macrophages or neurons. (A and B) On day 4 p.i., the viral load was measured by qPCR (A) or FFA (B). (C–E) 
IL-6 and TNF-α production and Ccl2, Ccl7, and Cxcl10 RNA levels were measured on day 4 by Bio-Plex or qPCR, respectively. Data are presented as the mean 
± SEM and are representative of 2 similar experiments (n = 4). (A–E) **P < 0.01 compared with the WT group (unpaired, 2-tailed Student’s t test). (F) 
Western blot assay for p38MAPK activation. One representative sample of two per group is shown. (G and H) BV2 cells were infected at a MOI of 0.02 with 
WNV 385-99 and treated with Smaducin-6 or control peptides 1 hour p.i. (G) Viral load was measured by qPCR on day 4 p.i. (H) Cytokine and chemokine 
levels were measured on day 4 by qPCR. Data are presented as the fold increase compared with mock-infected cells (mean ± SEM) and represent 8 sam-
ples pooled from 2 independent experiments.
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cleavage maturation by the cellular protease furin. Mutation of the 
furin recognition site of the prM of the tick-borne encephalitis virus 
resulted in secretion of the smaller subviral particles. Altogether, 
our data suggest that Peli1 is involved in WNV attachment, entry, 
and assembly. The smaller virions generated from Peli1–/– cells had 
reduced replication rates in WT cells and triggered attenuated 
inflammatory responses in these cells, all of which contributed to 
a higher resistance in WT mice. These results further support our 
hypothesis that Peli1 mediates inflammatory responses and pro-
motes WNV encephalitis by facilitating virus replication. Consis-
tent with our findings in the mouse model, we also demonstrate 
that Peli1 expression is associated with WNV infection and inflam-
matory cell activation in postmortem hippocampal tissues from 
patients who died of acute WNV encephalitis. Results from this 
study provide us with a better understanding of the mechanisms 
by which WNV induces lethal encephalitis. We believe our findings 
will ultimately help to identify new therapeutic targets such as Peli1 
and lead to the development of virus replication inhibitors to pre-
vent and treat WNV-induced encephalitis. Last, Peli1 is expressed 
on many cell types and is highly enriched in CNS tissues. Future 
studies will be needed to determine the role of Peli1 in other virus 
models, in particular in neurotropic flavivirus models.
Methods
Further information can be found in the Supplemental Methods.
Mice. Five- to eight-week-old C57BL/6 (B6) mice were purchased 
from The Jackson Laboratory. Peli1–/– mice (on a B6 background) (2, 
51) were bred at UTMB. Both female and male mice were used in this 
study and were age and sex matched. Mice were inoculated i.p. with 
100 FFU WNV 385-99 (52, 53) or WNV 385-99 passaged once in WT 
and Peli1–/– macrophages. In some experiments, mice were challenged 
intracranially (i.c.) with 5 FFU WNV 385-99.
Cells. BM-derived DCs, macrophages, and primary microglia cul-
tures were isolated as described previously (2, 54). Neurons were gen-
erated as described previously (55), with slight modifications. After the 
dissection and dissociation of cortices of E18.5 mouse embryos, cells 
were enriched using a Mouse Neuron Isolation Kit (Miltenyi Biotec) 
and cultured for 5 days in neurobasal medium containing B-27 supple-
ment (Invitrogen, Thermo Fisher Scientific). BV2 cells were provided 
in WNV-infected Peli1–/– mice. Our results suggest a role of Peli1 
as a positive regulator of innate immunity. There are conflicting 
reports on the role of Peli1 in the induction of type I IFN respons-
es during viral infection. For example, Xiao et al. found that Peli1 
negatively regulates IFN signaling in microglia and macrophages 
during vascular stomatitis viral infection in the CNS (41). Anoth-
er group has shown that Peli1 interacts with DEAF1 and positively 
regulates IFN-β production following Sendai virus infection (42). 
While our results are in line with the latter finding, the main differ-
ence between ours and the previous findings is that Peli1 positively 
mediates immune induction predominantly via the facilitation of 
WNV entry and replication.
The WNV life cycle includes attachment/entry, translation, 
RNA replication, and egress of viral particles. Although the virus 
relies heavily on host proteins during its life cycle (43, 44), our 
understanding of the molecular interactions of viruses and mam-
malian host cells and their effects on viral pathogenesis is limited. 
Previous RNA interference screening of human genes responsible 
for interaction with WNV proteins identified the Ub ligase CBLL1 as 
being critical for WNV internalization during in vitro infection (45). 
Several host factors, including AXL and TIM1, have been shown to 
be involved in flavivirus replication from in vitro cell culture stud-
ies. However, their roles remain to be confirmed in vivo (46–48). 
In this study, by using both in vivo and in vitro models, we identi-
fied Peli1 as a host factor required for WNV initial cell attachment 
and entry, a process that further promotes TLR-mediated inflam-
matory responses in mouse and human neural cells. Interestingly, 
the size of the virions generated after passaging WT WNV once in 
Peli1–/– cells was markedly reduced. We noted no genetic changes 
in the passaged viruses (data not shown). However, the reduc-
tion of virion size is likely due to an altered protein composition 
or changes in the ratio of viral proteins in the virions during virus 
assembly (49). In particular, the smaller viral particles produced 
in Peli1–/– cells are consistent with the size of recombinant subviral 
particles assembled in the endoplasmic reticulum during flavivirus 
infection in mammalian cells reported previously (50). The sub-
viral particles consist of the premembrane-E (prM-E) structural 
proteins, retain functional properties, and are transported from the 
endoplasmic reticulum through the secretory pathways to undergo 
Figure 8. Proposed model illustrating 
how Peli1 promotes virus replica-
tion and neuroinflammation during 
WNV infection. In the periphery, Peli1 
promotes WNV replication in macro-
phages and DCs and positively regulates 
antiviral innate immune responses in 
these cells. Peli1 also negatively medi-
ates IFN-γ production in T cells. Once 
the virus crosses the BBB and enters the 
CNS, Peli1 facilitates WNV replication 
in microglia and neurons and further 
boosts a robust inflammatory cytokine 
and chemokine production in these 
cells, which attracts more inflammatory 
cells infiltrated from the periphery and 
ultimately contributes to lethal WNV 
encephalitis.
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M cacodylate buffer (pH 7.3), to which 0.01% picric acid and 0.03% 
CaCl2 were added (electron microscopy [EM] fixative). The pellets 
were washed in 0.1 M cacodylate buffer followed by postfixation in 1% 
OsO4 in 0.1 M cacodylate buffer for 1 hour, washing, and then en bloc 
staining with 2% aqueous uranyl acetate for 20 minutes at 60°C. The 
pellets were next dehydrated in ethanol, processed through propylene 
oxide, and embedded in Poly/Bed 812 (Polysciences). Sections were 
cut on a Leica EM UC7 ultramicrotome, stained with lead citrate, and 
examined with a Philips CM-100 transmission electron microscope 
(TEM) at 60 kV. Images were acquired with a Gatan Orius SC200 
digital camera. In some experiments, supernatants of WNV-infected 
cells were concentrated on day 4 p.i. using 3-kDa spin columns (Sarto-
rius). The concentrated supernatants were centrifuged for 10 minutes 
at 3,000 g to remove debris. Next, nickel grids were incubated with 
clarified supernatants for 10 minutes followed by glutaraldehyde fix-
ation and 2% uranyl acetate staining. Micrographs were taken using a 
CM100 TEM (Philips).
Flow cytometry. Brain leukocytes were isolated as described pre-
viously (20) and stained with antibodies for cell-surface markers, 
including CD3 (eBioscience, clone 145-2C11); CD4 (eBioscience, 
clone GK1.5); CD8 (eBioscience, clone 53-6.7); CD11b (eBioscience, 
clone M1/70); Gr-1 (eBioscience, clone RB6-8C5); and CD45 (BD 
Biosciences, clone 30-F11), fixed with 1% paraformaldehyde in PBS, 
and examined with a C6 Flow Cytometer (BD Biosciences). Dead cells 
were excluded on the basis of forward and side light scatter.
Western blot analysis. Protein was dissolved in 1× SDS loading buffer, 
separated on SDS-PAGE gels, electroblotted onto nitrocellulose mem-
branes, probed with primary and secondary antibodies, and detected 
using a Pierce ECL System (Thermo Fisher Scientific). The primary anti-
bodies against phosphorylated p38 (p-p38) (Thr180/Tyr182, no. 9211s), 
p38 (no. 9212), p–NF-κB RelA (Ser 468, no. 3039), and NF-κB (no. 3034) 
were from Cell Signaling Technology. Mouse monoclonal anti–β-actin 
(MilliporeSigma, clone AC-15) was used as a loading control.
Histology. Mice were transcardially perfused with PBS. Brains 
and spleens were removed and placed in 4% paraformaldehyde (PFA) 
for 3 days at 4°C, followed by 70% ethanol before embedment in opti-
mal cutting temperature compound. H&E staining was performed at 
the Histopathology Laboratory Core of Baylor College of Medicine 
(Houston, Texas, USA).
Immunohistochemistry. Paraffin-embedded human hippocampal 
tissues were obtained from fatal WNV encephalitis cases (provided 
by Beth Levy, St. Louis University, St. Louis, Missouri, USA) and from 
control postmortem samples from patients without neurologic diseas-
es. Sections were deparaffinized in xylene, rehydrated in serial dilu-
tions of ethanol, and boiled in citrate buffer (pH 6.0) for 30 minutes 
for antigen retrieval. Next, the sections were incubated for 2 hours at 
room temperature in blocking solution (10% serum and 2% Tween-20 
in PBS) to permeabilize and block nonspecific binding. This was fol-
lowed by incubation with primary antibodies against Peli1 (Santa Cruz 
Biotechnology, sc-271065, 1:50), WNV antigen (UTMB WRCEVA), 
T35502, 1:500), and NeuN (MilliporeSigma, clone A60, 1:20) or iso-
type-matched IgG in PBS supplemented with10% serum overnight 
at 4°C. After washing, the sections were incubated for 1 hour at room 
temperature with fluorescently conjugated secondary antibodies (Life 
Technologies, Thermo Fisher Scientific, 1:500). Autofluorescence was 
darkened using 5% Sudan black B (diluted in 70% ethanol) incubated 
for 10 minutes. After washing, nuclei were counterstained with DAPI, 
by A. Cardona (University of Texas San Antonio, San Antonio, Texas, 
USA). BM-DCs or macrophages, microglia, and BV2 cells were infect-
ed with WNV at a MOI of 0.1 or 0.02, and neurons were infected at 
a MOI of 0.003. SH-SY5Y cells were cultured in F12K medium and 
Eagle’s minimal essential media (EMEM) (Invitrogen, Thermo Fish-
er Scientific) and seeded in a 6-well plate for 1 day and then replaced 
with fresh medium containing 30 μM retinoic acid (MilliporeSigma) 
and 1% B-27 Supplements (Gibco, Thermo Fisher Scientific, catalog 
17504) for 5 days, and the cells differentiated into neurons. Sma-
ducin-6 or Pal-Scram peptides (34) were purchased from MilliporeSig-
ma and used at 100 nm 1 hour after infection. Supernatants and cells 
were harvested 24 and 96 hours p.i. to measure the viral load and cyto-
kine production. In some experiments, WT and Peli1–/– macrophages 
or neurons were infected with WNV 385-99. Culture supernatants 
were then harvested on day 4 for virus titration by FFA. Equal titers of 
viruses from WT and Peli1–/– culture were subsequently used for in vivo 
and in vitro infection studies.
FFA. Vero cells were incubated with sample dilutions for 1 hour. 
A semisolid overlay containing 0.8% methylcellulose (MilliporeSig-
ma), 3% FBS, 1% penicillin-streptomycin, and 1% L-glutamine was 
added. At 48 hours, the semisolid overlay was removed and cells were 
washed and fixed with 1:1 of an acetone/methanol solution for at least 
30 minutes at –20°C. Cells were next subjected to immunohistochem-
ical staining with a rabbit WNV polyclonal antibody (World Reference 
Center for Emerging Viruses and Arboviruses [WRCEVA], T35502) 
followed by goat anti-rabbit HRP–conjugated IgG (KPL, 474-1516) for 
1 hour. Next, cells were incubated with a peroxidase substrate (VEC-
TOR Laboratories) until color developed. The number of foci was used 
to calculate viral titers.
qPCR. Samples were resuspended in TRIzol (Invitrogen, Thermo 
Fisher Scientific) for RNA extraction. cDNA was synthesized by using 
a qScript cDNA Synthesis Kit (Bio-Rad). The sequences of the prim-
er sets for WNV envelope (Wnve), Peli1, Peli2, and Peli3 and cytokine 
cDNA and PCR reaction conditions were described previously (2, 25, 
36, 53, 56). The assay was performed using the CFX96 Real-time PCR 
System (Bio-Rad). Gene expression was calculated on the basis of Ct 
values using the following formula: 2^ –[Ct(target gene)-Ct(GAPDH or ACTB)] (53).
Viral attachment and entry assays. BM-macrophages were incubat-
ed with WNV (MOI of 3 or 10) at 4°C for 1 hour, allowing the virus to 
attach to the cell surface. After 1 hour of incubation, infected cells were 
washed 3 times with cold PBS to remove unbound virions. Cell-sur-
face–associated viruses were removed by washing with cold alkaline 
high-salt solution (1 M NaCl and 50 mM sodium bicarbonate, pH 9.5). 
After 2 cold PBS washes, cells were harvested and suspended in 3 ml 
DMEM medium containing 2% FBS. Total cells were collected by cen-
trifugation at 1,000 g for 5 minutes. The cell pellets were resuspended 
in TRIzol for RNA extraction to measure viral titers by qPCR. Some 
cells were further incubated at 37°C to initiate viral entry. At 1.5 and 
5 hours p.i., the infected cells were stringently washed to remove free 
virus as well as cell-surface–associated virus, and intracellular viral 
RNA levels were quantified by qPCR.
Transmission electron microscopy. Cells were washed with ice-cold 
PBS and incubated on ice for 15 minutes before exposure to WNV (MOI 
= 10) for 1 hour. Cells were then rinsed with ice-cold PBS, resuspended 
in prewarmed media, and incubated at 37°C. At 0 hours, 5 minutes, 
and 10 hours p.i., cells were pelleted and fixed for at least 1 hour in 
a mixture of 2.5% formaldehyde and 0.1% glutaraldehyde in 0.05 
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